Dearborn Partners LLC Sells 4,467 Shares of Zoetis Inc. $ZTS

Dearborn Partners LLC trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 3.5% during the third quarter, HoldingsChannel reports. The fund owned 123,176 shares of the company’s stock after selling 4,467 shares during the quarter. Dearborn Partners LLC’s holdings in Zoetis were worth $18,023,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. Halbert Hargrove Global Advisors LLC lifted its holdings in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares during the period. NewSquare Capital LLC lifted its holdings in Zoetis by 69.1% during the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after buying an additional 85 shares during the period. Financial Consulate Inc. bought a new stake in shares of Zoetis in the 3rd quarter valued at about $39,000. SJS Investment Consulting Inc. increased its stake in shares of Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after buying an additional 257 shares during the period. Finally, TruNorth Capital Management LLC bought a new position in shares of Zoetis during the third quarter worth about $42,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Up 1.1%

NYSE:ZTS opened at $128.73 on Friday. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.00. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock has a market capitalization of $54.34 billion, a price-to-earnings ratio of 21.38, a PEG ratio of 1.94 and a beta of 0.96. The firm has a fifty day simple moving average of $125.41 and a two-hundred day simple moving average of $134.80.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Analyst Ratings Changes

Several analysts recently commented on the company. Barclays assumed coverage on Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price on the stock. Bank of America increased their price objective on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. KeyCorp initiated coverage on shares of Zoetis in a report on Thursday, November 20th. They issued a “sector weight” rating on the stock. Morgan Stanley set a $160.00 price target on Zoetis in a report on Thursday, December 18th. Finally, HSBC set a $140.00 price objective on Zoetis in a research report on Wednesday, December 10th. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.